LONDON — European regulators are on the verge of rejecting an ALS drug from Amylyx Pharmaceuticals, all but dooming the medicine’s chances of entering the E.U. market for now.
The negative recommendation issued Friday by a European Medicines Agency committee is not a surprise. Last month, Amylyx said that the agency was headed toward a negative review. But it amounts to a serious blow to the drug, which last year won U.S. and Canadian authorization, and is likely to stoke the debate about whether the medicine is truly effective.
“The agency had concerns that the main study did not show convincingly that Albrioza was effective in slowing down the worsening of the disease,” the EMA’s review found. “Data on survival were also not reliable, given the way the data were collected and analyzed.”
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect